Targeted Genetics, University of North Carolina deal

TGEN obtained from the university an option to license exclusive rights to an engineered form of the Factor VIII gene (lacking the B-domain) that reduces its size and allows it to be encoded by a single adeno-associated viral (AAV) vector to treat hemophilia A. ...